Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis - Scorecard - MDSpire
Advertisement
Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis
Clinical Scorecard: Targeted Proteomics and Integrative Approaches Reveal the Plasma Exosomal Profile in Thyroid Disorders, Focusing on Papillary Thyroid Carcinoma Associated with Hashimoto’s Thyroiditis
At a Glance
Category
Detail
Condition
Key Mechanisms
Differentially expressed proteins (DEPs) involved in extracellular matrix-receptor interactions and immune response pathways, with specific examples.
Target Population
Care Setting
Key Highlights
PTC accounts for approximately 90% of thyroid cancer cases.
HT is a common benign thyroid disorder and a potential risk factor for PTC.
45 differentially expressed proteins were identified between PTC-W and HT.
SVEP1 and IGKV3-7 are highlighted as promising plasma exosomal biomarkers for PTC in patients with HT.
Exosomes may serve as novel diagnostic biomarkers for thyroid diseases.
Guideline-Based Recommendations
Diagnosis
Management
Consider individualized treatment plans based on biomarker profiles.
Monitoring & Follow-up
Regular follow-up imaging and biomarker assessment for high-risk patients.
Risks
Patient & Prescribing Data
Patients aged 18-80 years with definitive diagnoses of PTC, PTC-W, HT, and healthy controls.
Current research emphasizes the need for biomarkers to identify high-risk populations for PTC among HT patients.
Clinical Best Practices
Consider the role of exosomal proteins in the differential diagnosis of PTC from HT.
Implement integrative approaches combining proteomics and bioinformatics in research.
